---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-057689"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T21:29:58.149190+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics reports $18.3M cash as of Q1 2024, VIRAGE enrollment on track for Q3 completion

## Summary
- Cash and cash equivalents $18.3M at March 31, 2024, expected to fund operations into Q1 2025.
- R&D expenses $3.5M in Q1 2024, up 16% YoY due to clinical trial costs.
- VIRAGE Phase 2b trial for VCN-01 in metastatic PDAC expected to complete enrollment in Q3 2024.
- Positive topline data from Phase 1 trial of VCN-01 in pediatric refractory retinoblastoma – study committee deemed results positive.
- Licensing discussions ongoing for SYN-020 intestinal alkaline phosphatase asset.

## SEC filing metadata
- accession: 0001104659-24-057689
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/0001104659-24-057689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/tm2413496d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-057689
- JSON: https://secwatch.observer/filing/0001104659-24-057689.json
- Plain text: https://secwatch.observer/filing/0001104659-24-057689.txt

## Key facts
- Earnings Releases
  Theriva Biologics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 7, 2024, Theriva Biologics, Inc., a Nevada corporation (the “Registrant”) issued a press release that included financial information for its quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/894158/000110465924057689/0001104659-24-057689-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.